NanoViricides to Present Antiviral Pipeline Updates at PODD 2025 Conference

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to prevent viral escape, will present at the PODD 2025 Conference on Monday, October 27, at 3 p.m. ET in Track 5A at the Westin Copley Hotel in Boston. President and Executive Chairman Anil R. Diwan, PhD, will provide updates on the company's antiviral drug pipeline and platform technologies available for licensing. This presentation comes at a critical time as the company advances its lead candidate, NV-387, toward Phase II clinical trials for MPox and respiratory viral infections.

The company's nanoviricide technology platform represents a novel approach to antiviral therapy, creating special purpose nanomaterials that target viruses through multiple mechanisms. This technology is licensed from TheraCour Pharma, Inc., with whom NanoViricides has a Memorandum of Understanding for developing drugs based on these technologies for all antiviral infections. The company's business model relies on licensing technology from TheraCour for specific application verticals of specific viruses, as established at its foundation in 2005. More information about the company's technology and approach can be found at https://www.nanoviricides.com.

NV-387, the company's lead drug candidate, has shown strong efficacy in preclinical studies against multiple viruses including RSV, Influenza A, and Coronaviruses. The broad-spectrum nature of this candidate positions it as a potential solution for multiple respiratory viral infections, including COVID-19 and Long COVID. The company plans to develop NV-387 as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Another advanced candidate in the pipeline is NV-HHV-1 for the treatment of Shingles.

NanoViricides holds exclusive worldwide perpetual licenses for several viral disease treatments through its relationship with TheraCour, which licenses the underlying nanomedicine technology from AllExcel. The licensed fields include Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company intends to obtain additional licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful.

The company's presentation at the PODD 2025 Conference represents an important opportunity to showcase its progress to the pharmaceutical and investment communities. As with all drug development efforts, the path forward requires substantial capital and carries inherent risks, but the potential impact of successful broad-spectrum antiviral treatments could significantly advance global public health preparedness against emerging viral threats. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.